文献速递腹部技术与安全MR

转移性葡萄膜黑色素瘤:3个月MRI肿瘤负荷与生长率预测生存

Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp
RSS 订阅 · Diagnostic and Interventional Imaging · 2026-03-02

本研究回顾性纳入88例接受tebentafusp治疗的转移性葡萄膜黑色素瘤肝转移患者,在基线及3个月行肝脏MRI并分割肝转移灶,计算总肿瘤体积与指数生长率。结果显示3个月总肿瘤体积(TTVm3)和生长率(TGRm3)独立预测总生存,基于二者构建的三级MRI风险评分C指数为0.79,优于ctDNA模型及RECIST客观反应。

要点

  • 3个月肝脏MRI总肿瘤体积和生长率是独立预后指标,基线肿瘤体积与RECIST反应不具独立预测价值。
  • MRI风险评分按TTVm3与TGRm3中位切点分三层,生存曲线分离良好,C指数0.79。
  • tebentafusp治疗中,3个月MRI动态指标优于ctDNA和RECIST,可用于风险分层与治疗决策。

核心结论

  • 接受tebentafusp治疗的转移性葡萄膜黑色素瘤患者中,3个月MRI总肿瘤体积和指数生长率可提供超越基线影像、ctDNA和RECIST的独立预后信息。
  • 基于TTVm3与TGRm3中位切点的三级MRI风险评分生存分层良好,C指数为0.79,优于ctDNA模型和RECIST客观反应。

研究设计与样本

  • 回顾性研究,纳入2018至2022年间接受tebentafusp治疗的88例转移性葡萄膜黑色素瘤患者,其中女性52例、男性36例,中位年龄59.0岁(Q1, 52.0; Q3, 66.5; 范围30–77岁)。
  • 所有患者在启动tebentafusp治疗时(基线)及3个月时均接受肝脏MRI检查,对肝转移灶进行分割并计算TTV0、TTVm3与TGRm3(%/月)。
  • 可用时在同一时间点对循环肿瘤DNA(ctDNA)进行定量;使用Cox模型和Harrell一致性指数(C指数)评估与总生存的关联,95%CI经1000次迭代自助重抽样获得。

关键影像表现/征象

  • 基线与3个月肝脏MRI上对肝转移灶进行逐层分割,计算总肿瘤体积TTV0与TTVm3,并计算两次扫描间的指数肿瘤生长率TGRm3(%/月)。

诊断标准与关键数值

  • 多变量分析中,TTVm3每加倍,死亡风险HR为1.25(95%CI: 1.15–1.35),P<0.001;TGRm3每增加10%/月,HR为1.18(95%CI: 1.08–1.29),P<0.001。
  • 基线肿瘤体积TTV0与RECIST客观反应在多变量分析中无独立预测意义。
  • MRI风险评分为三层,基于中位数TTVm3与TGRm3切点联合构建;三层生存曲线的log-rank检验P<0.001。
  • MRI风险评分C指数为0.79(自助法95%CI: 0.71–0.86),优于ctDNA模型(C指数0.73,P=0.01)和RECIST客观反应(C指数0.65,P<0.001)。

临床应用与阅片要点

  • 对于接受tebentafusp治疗的葡萄膜黑色素瘤肝转移患者,除常规RECIST评估外,应在3个月肝脏MRI上测量肝转移灶总肿瘤体积并计算生长率,用于风险分层。
  • 当3个月TTVm3较高或TGRm3较快时,提示生存预后不良,可在报告中提示临床综合评估后续治疗策略。

局限性

  • 本研究为回顾性设计。
  • ctDNA并非在所有患者所有时间点均可用。
英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study was to determine whether liver magnetic resonance imaging (MRI)-derived tumor burden and growth rate at 3 months better predict overall survival (OS) than baseline imaging, circulating tumor DNA (ctDNA), and RECIST objective response in patients with hepatic metastases from metastatic uveal melanoma (mUM) treated with tebentafusp.

MATERIALS AND METHODS: A total of 88 patients with mUM treated with tebentafusp between 2018 and 2022 who underwent MRI examination at baseline and at three months following initiation of tebentafusp were retrospectively included. There were 52 women and 36 men, with a median age of 59.0 years (Q1, 52.0; Q3, 66.5; range: 30-77 years). Hepatic metastases were segmented to compute total tumor volumes at baseline (TTV0) and at 3 months (TTVm3) and the exponential tumor growth rate between scans (TGRm3, %/month). When available, ctDNA was quantified at the same time points. Associations with OS were assessed using Cox models and Harrell's concordance index (C-index) with 95 % confidence intervals obtained by 1,000-iteration bootstrap resampling. A three-tier MRI risk score combined median-based TTVm3 and TGRm3 cutoffs.

RESULTS: In multivariable analysis, greater TTVm3 and TGRm3 were independently associated with shorter OS (hazard ratio [HR] per doubling of TTVm3, 1.25; 95 % confidence interval [CI]: 1.15-1.35; HR per +10 %/month TGRm3, 1.18; 95 % CI; 1.08-1.29; both P < 0.001), whereas baseline tumor volume and RECIST objective response were not. The MRI risk score yielded three well-separated OS curves (log-rank P < 0.001) and a C-index of 0.79 (bootstrap 95 % CI: 0.71-0.86), outperforming ctDNA-based models (C-index, 0.73; P = 0.01) and RECIST objective response (C-index, 0.65; P < 0.001).

CONCLUSION: Dynamic liver MRI biomarkers in patients with mUM under tebentafusp, particularly month-3 total tumor volume and growth rate, provide independent prognostic information beyond baseline imaging, ctDNA, and RECIST and support MRI-based risk stratification as a central decision tool in mUM.

来源:Diagnostic and Interventional Imaging,查看原文。版权归原作者所有。

引用

  1. Diagnostic and Interventional Imaging:Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp
  2. Ramtohul, Jasawant, Sandoval, et al. Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp. Diagn Interv Imaging. 2026. PMID: 41775639. doi:10.1016/j.diii.2026.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。